Oxgene, a biotechnology company designing and developing scalable gene therapy technologies, has announced the launch of its scalable, plasmid-free manufacturing system for Adeno-associated virus (AAV). Oxgene’s new TESSA technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture at scale. AAV is a popular choice of viral vector to deliver gene therapies to patients. […]
The post Oxgene Introduces Tessa Technology for plasmid-free manufacturing system for Adeno-associated virus first appeared on World Pharma Today.